Phaseline

Companies › Ascletis Pharma (China)

Ascletis Pharma (China): clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 3; Metabolic and endocrine; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ASC30–Phase 3ObesityJul 2028
ASC36 Injection
GLP-1 receptor agonist
–Phase 1Chronic Weight ManagementApr 2027
ASC35 Injection B
Dual GLP-1/GIP receptor agonist
–Phase 1Chronic Weight ManagementJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07893106ASC36 InjectionPhase 1Chronic Weight ManagementMetabolic and endocrineApr 2027
NCT07893093ASC36 InjectionPhase 1Chronic Weight ManagementMetabolic and endocrineJun 2027
NCT07842640ASC35 Injection BPhase 1Chronic Weight ManagementMetabolic and endocrineJun 2027
NCT07743463ASC30Phase 3ObesityMetabolic and endocrineJul 2028
NCT07743450ASC30Phase 3ObesityMetabolic and endocrineJul 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

The United Bio-Technology (Hengqin) JCR Pharmaceuticals Innovent Biologics Technology Limited (Shanghai R&D Center) Laekna Viking Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.